Sanofi (SNY) Stock Forecast & Price Target

$50.74 0.00 (0.00%)

As of 01/17/2025 04:00 PM Eastern

Sanofi - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 3 Analyst Ratings

Sell
0

Hold
1

Buy
2

Based on 3 Wall Street analysts who have issued ratings for Sanofi in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 1 has given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for SNY.

Consensus Price Target

$57.50
13.32% Upside

According to the 3 analysts' twelve-month price targets for Sanofi, the average price target is $57.50. The highest price target for SNY is $60.00, while the lowest price target for SNY is $55.00. The average price target represents a forecasted upside of 13.32% from the current price of $50.74.

Get the Latest News and Ratings for SNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors.

SNY Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	1 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$57.50	$57.50	$57.50	$60.00
Forecasted Upside	13.32% Upside	20.52% Upside	7.96% Upside	17.58% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Hold

SNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sanofi Stock vs. The Competition

Type	Sanofi	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.82	2.52
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	13.32% Upside	24,741.17% Upside	12.44% Upside
News Sentiment Rating	Positive News See Recent SNY News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Citigroup 3 of 5 stars	P. Verdult Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/26/2024	Argus 2 of 5 stars		Boost Target	Buy ➝ Buy	$55.00 ➝ $60.00	+13.92%
1/23/2024	Morgan Stanley 3 of 5 stars		Initiated Coverage	Equal Weight	$55.00	+8.20%
12/5/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
10/30/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
9/5/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
7/14/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
4/28/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Hold ➝ Sell
3/27/2023	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:25 PM ET.

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 12, 2025. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

Sanofi
Bull Case

Here are some ways that investors could benefit from investing in Sanofi:

Sanofi recently reported a quarterly earnings per share (EPS) of $1.57, significantly exceeding the consensus estimate of $0.22, indicating strong financial performance and effective management.
The company has a market capitalization of $118.77 billion, reflecting its substantial size and stability in the healthcare sector, which can be attractive to investors seeking reliable investments.
Sanofi's stock is currently priced at $46.80, which is near its 12-month low of $45.22, potentially offering a buying opportunity for investors looking for undervalued stocks.
With a return on equity of 27.45%, Sanofi demonstrates effective use of equity financing to generate profits, which can be appealing to investors focused on profitability metrics.
The company has shown a revenue increase of 12.3% compared to the same quarter last year, indicating growth potential and a positive outlook for future earnings.

Sanofi
Bear Case

Investors should be bearish about investing in Sanofi for these reasons:

Despite the positive earnings report, Sanofi's revenue of $13.44 billion fell short of analysts' expectations of $16.59 billion, which may raise concerns about future sales performance.
The company's quick ratio is 0.65, suggesting that it may struggle to meet short-term liabilities without selling inventory, which could be a red flag for liquidity.
Sanofi's P/E ratio of 23.88 indicates that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
Recent analyst ratings have been mixed, with some downgrading the stock from "buy" to "hold," indicating uncertainty about its future performance.
The beta of 0.58 suggests that Sanofi's stock is less volatile than the market, which may not appeal to investors looking for high-risk, high-reward opportunities.

SNY Forecast - Frequently Asked Questions

: According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Sanofi is $57.50, with a high forecast of $60.00 and a low forecast of $55.00.
: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There is currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNY shares.
: According to analysts, Sanofi's stock has a predicted upside of 13.32% based on their 12-month stock forecasts.
: Analysts like Sanofi more than other "medical" companies. The consensus rating for Sanofi is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:SNY) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sanofi (SNY) Stock Forecast & Price Target